Adragos Pharma, a German CDMO, has snapped up one of Europe’s largest sterile injectables production plants for an undisclosed price from Sanofi.
The deal marks the latest site transaction between Adragos and Sanofi and, combined with Adragos’ existing filling operations in France and Switzerland, positions the company as one of the top sterile injectables CDMOs on the continent, according to an April 1 press release.
The former Sanofi sterile fill-finish facility, equipped for commercial-scale manufacturing, is located just outside of Paris in Maisons-Alfort, France, and also supports production of liquid and lyophilized vials.
The financial terms of the deal were not disclosed.
Adragos said it plans to retain the employees currently working at the plant to help ensure continuity of service. The "complete talent integration" marks a "major strategic asset" for the future of the former Sanofi facility, according to Adragos.
“Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey,” Andreas Raabe, M.D., Adragos founder and CEO, said in a statement. “Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform.”
In 2023, Adragos and Sanofi inked a deal that gave the CDMO a drug manufacturing facility in Kawagoe, Japan, near Tokyo. The site, which has been in operation for more than half a century, has been kitted out for the production of oral solids and sterile liquids.
Financial details of that deal weren’t disclosed either, however, the two sides did ink a separate long-term supply agreement that has Adrogos helping manufacture Sanofi products for five years, serving as a strategic partner for the French pharma in Japan.